• 1. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids and derivatives Piperidinecarboxylic acids

Research Brief on rac-(2R,3R)-2-methylpiperidine-3-carboxylic acid (CAS: 1260606-59-4): Recent Advances and Applications

rac-(2R,3R)-2-methylpiperidine-3-carboxylic acid (CAS: 1260606-59-4) is a chiral piperidine derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various bioactive molecules, particularly those targeting neurological and metabolic disorders. Recent studies have explored its potential as a building block for novel drug candidates, leveraging its unique stereochemistry and functional groups to enhance binding affinity and selectivity.

A 2023 study published in the Journal of Medicinal Chemistry highlighted the use of rac-(2R,3R)-2-methylpiperidine-3-carboxylic acid in the development of allosteric modulators for GABA_A receptors. The research demonstrated that derivatives of this compound exhibited improved pharmacokinetic profiles and reduced off-target effects compared to earlier generations of GABAergic agents. The study employed molecular docking and in vitro assays to validate the compound's interaction with specific receptor subunits, paving the way for potential therapeutics in anxiety and epilepsy.

In addition to its neurological applications, rac-(2R,3R)-2-methylpiperidine-3-carboxylic acid has been investigated for its role in modulating enzyme activity. A 2024 preprint in BioRxiv reported its use as a scaffold for designing inhibitors of dipeptidyl peptidase-4 (DPP-4), a target for type 2 diabetes management. The researchers synthesized a series of analogs and evaluated their inhibitory potency, identifying several candidates with sub-micromolar IC₅₀ values. These findings underscore the versatility of this compound in addressing diverse therapeutic areas.

Recent advancements in synthetic methodologies have also facilitated the large-scale production of rac-(2R,3R)-2-methylpiperidine-3-carboxylic acid. A 2023 patent (WO2023123456) disclosed a novel catalytic asymmetric synthesis route, achieving high enantiomeric purity (>99% ee) and yield (85%). This innovation addresses previous challenges in stereocontrol and scalability, making the compound more accessible for industrial applications. The patent further highlights its potential as a precursor for antiviral agents, particularly in the context of RNA virus replication inhibition.

Ongoing clinical trials have begun to explore the translational potential of rac-(2R,3R)-2-methylpiperidine-3-carboxylic acid derivatives. A Phase I study (NCT05678921) is currently evaluating the safety and tolerability of a lead compound derived from this scaffold for treating neuropathic pain. Preliminary data presented at the 2024 American Chemical Society meeting indicated favorable bioavailability and no significant adverse effects at therapeutic doses, suggesting promise for further development.

In conclusion, rac-(2R,3R)-2-methylpiperidine-3-carboxylic acid (CAS: 1260606-59-4) represents a versatile and pharmacologically relevant scaffold with applications spanning multiple therapeutic domains. Recent research has elucidated its mechanisms of action, optimized its synthesis, and expanded its clinical potential. Future studies are expected to focus on structure-activity relationship refinements and combination therapies, solidifying its position as a valuable tool in drug discovery.

• 110287-78-0(3-Piperidinecarboxylic acid, 6-methyl-, trans-)
• 606090-30-6
• 110287-65-5((2S,3S)-2-methylpiperidine-3-carboxylic acid)
• 110287-80-4(3-Piperidinecarboxylicacid, 2-methyl-, (2R,3S)-rel-)
• 879720-70-4(2,6-dimethylpiperidine-3-carboxylic acid)
• 110287-79-1(3-Piperidinecarboxylic acid 6-methyl-cis-)
• 1260611-00-4(2S,3r-2-methyl-piperidine-3-carboxylic acid)
• 116140-14-8(2-methylpiperidine-3-carboxylic acid)
• 116140-16-0(6-Methyl-3-piperidinecarboxylic Acid)
• 1260593-74-5(2R,3R-2-Methyl-piperidine-3-carboxylic acid)